THE EVIDENCE OF PHARMACOECONOMIC PROFITABILITY AND EASIBIUTYOF DOMESTIC TRASTUZUMAB BIOSIMILAR USING IN HER2-POSTIVE BREAST CANCER
Abstract
A comparative pharmacoeconomic study of the biosimilar Trastuzumab (KFQ Kazakhstan) and the original drug Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) using in the breast cancer treatment was carried out using the methods of «Cost minimization» and «Budget impact». The pharmacoeconomic advantage of the biosimilar is established, which is expressed in lower costs with equal efficiency. Replacing the original drug with a biosimilar should save the health budget.
About the Authors
M. A. Nurgaziyev
Karaganda State University named after Ye. А. Buketov
Kazakhstan
Kazakhstan
A. Ye. Gutyayev
Center for Life Sciences NLA, Nazarbayev University
Kazakhstan
Kazakhstan
S. K. Zhaugasheva
Karaganda medical university
Kazakhstan
Kazakhstan
L. I. Piven
Karaganda medical university
Kazakhstan
Kazakhstan
T. V. Kim
Karaganda medical university
Kazakhstan
Kazakhstan
References
1. Аксентьева М. А. Kлинико-экономический анализ (оценка, выбор медицинских технологий и управления качеством медицинской помощи) /М. А. Авксентьева, Б. В. Герасимов, М. B. Сура. - М.: Ньюдиамед, 2004. - 404 с.
2. Здоровье населения Республики Казахстан и деятельность организаций здравоохранения в 2018 году: Стат. жинак. - Нур-Султан, 2019. - 324 б.
3. О внесении изменения в приказ Министра здравоохранения Республики Казахстан от 8 декабря 2017 года № 931 «Об утверждении Казахстанского национального лекарственного формуляра» Приказ Министра здравоохранения Республики Казахстан от 25 апреля 2019 года №КР ДСМ-51.
4. Ягудина Р. И. Теоретические основы фармакоэкономического метода: анализ «влияния на бюджет» /Р. И. Ягудина, А. Ю. Куликов //Фармакоэкономика. - 2011. - Т. 4, №2. -C. 18-26.
5. Adjuvant trastuzumab in HER2-positive breast cancer /D. Slamon, W. Eiermann, N. Robert et al. //N. Engl. J. Med. - 2011. - V. 365. - P. 1273-1283.
6. Are Biosimilars the Future of Oncology and Haematology? /P. Zinzani, M. Dreyling, W. Gradishar //Drugs. - 2019. - V. 79 (15). - P. 1609-1624.
7. Cesarec A. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia /A. Cesarec, R. Likic // Appl. Health Econ. Health Policy. - 2017. - V. 15 (2). - P. 277-286.
8. Chang H. R. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer //Cancer. - 2010. - V. 116. - P. 2856-2867.
9. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer //J. Comp. Eff. Res 10.2217/cer-2017-004
10. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial /L. Gianni, T. Pienkowski, Y. H. Im et al. //Lancet Oncol. - 2012. - V. 13. - P. 25-32.
11. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 /E. A. Perez, E. H. Romond, V. J. Suman et al. //J. Clin. Oncol. - 2011. - V. 29. - P. 3366-3373.
12. Global Cancer Statistics 2018: GLO-BOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries /F. Bray, J. Ferlay, I. Soerjomataram et al. //CA Cancer J. Clin The online GLOBOCAN 2018 database is accessible at http://gco.iarc.fr/, as part of IARC's Global Cancer Observatory.
13. https ://ba igenews.kz/ news/ ra k_moloch -noi_zhelezi_lidi ruet_sred i_on koza boleva n i i_v_kaza h stane/ (дата обращения: 26.01.2020 г.)
14. https://gco.iarc.fr/today/home (дата обращения: 26.01.2020 г.)
15. https://mk-kz.kz/social/2019/03/14/v-kazakhstane (дата обращения: 26.01.2020 г.)
16. https://tengrinews.kz/medicine/nazva-nyi-samyie-rasprostranennyie-vidyi-raka-u-kazahstantsev-365245/ (дата обращения: 26.01.2020 г.)
17. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets /R. A. Clynes, T. L. Towers, L. G. Presta et al. //Nat. Med. - 2000. - V. 6. - P. 443-446.
18. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group /M. Marty, F. Cognetti, D. Maraninchi et al. //J. Clin. Oncol. -2005. - V. 23. - P. 4265-4274.
19. Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer /S. Hamizi, G. Freyer, N. Bakrin et al. //OncoTargets Ther. - 2013. - V. 6. - P. 89.
20. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars /L. Barbier, P. Declerck, S. Simoens //Br. J. Cancer. - 2019. - V. 121(3). -P. 199-210.
21. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer /M. J. Pic-cart-Gebhart, M. Procter, B. Leyland Jones et al. N. Engl. //J. Med. - 2005. - V. 353. - P. 1659-1672.
Review
For citations:
Nurgaziyev M.A., Gutyayev A.Ye., Zhaugasheva S.K., Piven L.I., Kim T.V. THE EVIDENCE OF PHARMACOECONOMIC PROFITABILITY AND EASIBIUTYOF DOMESTIC TRASTUZUMAB BIOSIMILAR USING IN HER2-POSTIVE BREAST CANCER. Medicine and ecology. 2020;(1):125-132. (In Russ.)
Views: 208
Email this article 